GlassScriptPhysician profile
Adam Charles Ehrlich
NPI 1215197371
$117,437.28
in general payments reported to CMS, 2019-2025
12 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $3,300 · 2021: $3,300 · 2022: $7,088 · 2023: $37K · 2024: $29K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $28K · Honoraria: $3,900 · Travel and Lodging: $3,476 · Food and Beverage: $2,401 · Education: $93.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,405.50 |
| Consulting Fee | $27,870.00 |
| Honoraria | $3,900.00 |
| Travel and Lodging | $3,475.51 |
| Food and Beverage | $2,400.93 |
| Education | $93.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,381.39 | 2023-2025 | |
| Janssen Biotech, INC. | $24,968.79 | 2019-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $14,233.48 | 2022-2024 | Omvoh |
| Eli Lilly and Company | $13,104.02 | 2023-2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $12,032.50 | 2023-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $11,499.40 | 2023-2025 | |
| Pfizer INC. | $6,600.00 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $4,038.07 | 2023 | |
| Celgene Corporation | $420.00 | 2023-2024 | |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Concordia Pharmaceuticals INC. | $22.25 | 2019 | |
| Erbe USA INC | $15.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.